Organovo Holdings Inc (ONVO) : Think Investments Lp has sold out all of its stake in Organovo Holdings Inc during the most recent quarter, according to the disclosure filed by the company on Aug 15, 2016 with the SEC. The investment management company has sold out 1,380,026 shares of Organovo Holdings Inc which is valued at $6,306,719.
Other Hedge Funds, Including , Mangrove Partners sold out all of its stake in ONVO during the most recent quarter. The investment firm sold 100,000 shares of ONVO which is valued $457,000.Group One Trading reduced its stake in ONVO by selling 44,537 shares or 31.2% in the most recent quarter. The Hedge Fund company now holds 98,218 shares of ONVO which is valued at $448,856. Organovo Holdings Inc makes up approx 0.04% of Group One Trading’s portfolio.Raymond James Associates boosted its stake in ONVO in the latest quarter, The investment management firm added 7,072 additional shares and now holds a total of 24,493 shares of Organovo Holdings Inc which is valued at $111,933.Lehman Financial Resources boosted its stake in ONVO in the latest quarter, The investment management firm added 1,500 additional shares and now holds a total of 131,400 shares of Organovo Holdings Inc which is valued at $600,498. Organovo Holdings Inc makes up approx 0.30% of Lehman Financial Resources’s portfolio.Hightower Advisors reduced its stake in ONVO by selling 30 shares or 0.17% in the most recent quarter. The Hedge Fund company now holds 18,000 shares of ONVO which is valued at $82,260.
Organovo Holdings Inc closed down -0.07 points or -1.81% at $3.79 with 4,80,466 shares getting traded on Thursday. Post opening the session at $3.84, the shares hit an intraday low of $3.75 and an intraday high of $3.87 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.
Organovo Holdings Inc. is a commercial-stage company focused on developing and commercializing functional human tissues that can be employed in drug discovery and development biological research and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Company focuses on the generation of three-dimensional (3D) human tissues by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition architecture and function. Its platform NovoGen Bioprinters is focused on multiple 3D bioprinting technologies. Its commercial tissue exVive3D Human Liver Tissue is designed to be used for predictive preclinical testing of drug compounds. It is developing 3D Human Kidney Tissue which can be used for predictive preclinical testing of drug compounds.